FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Enoxaparin Sodium Injection
Status: Discontinuation
»Therapeutic Categories:

Sandoz (New 03/04/2016)

Company Contact Information:

Presentation Posting Date Related Information
300 mg/3.0 mL vials (NDC 0781-3122-93) N/A Sandoz Inc. has made a business decision to permanently discontinue Enoxaparin Sodium Injection 300 mg/3.0 mL vials. This decision was not related to efficacy, safety, or quality. Product will be available until approximately April 2016. The preservative free equivalent, Enoxaparin Sodium Injection in syringe, is available.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English